ClinicalTrials.gg
CompletedNCT06691126Updated Dec 4, 2024

Pharmacokinetic Study of Terpinolene in Healthy Subjects (PKT Study)

An interventional study of Terpinolene in olive oil in Pharmacokinetics of Terpinolene, sponsored by Singapore Institute of Food and Biotechnology Innovation. Completed at 1 site in Singapore. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Singapore Institute of Food and Biotechnology Innovation · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
21 Years to 50 Years
Sex
All
01

Study summary

The study aims to check if our prediction about the uptake, distribution, and elimination of terpinolene (a food additive commonly found in e.g. fruits and herbs) from the human body is accurate.

Read the detailed description

Traditionally, the toxicological hazards of chemical substances have been identified and evaluated using animal studies. With the global shift towards limiting the use of animals in human safety assessment, "Next Generation Risk Assessment (NGRA)" has been conceptualized as a human-relevant, exposure-led approach integrating in silico, in chemico and in vitro methodologies. Consequently, in silico physiologically based pharmacokinetic (PBPK) modelling strategies have emerged as a central component of the NGRA paradigm. By mapping compound behaviour (i.e. absorption, distribution, metabolism and excretion) in the body to a physiologically realistic compartmental structure comprising various organs connected by the circulating blood system, PBPK models (i) provide the link between in vitro hazard data and human-relevant exposures and (ii) enable conversion of external doses to internal exposures which can then be compared to internal thresholds of toxicological concern (iTTC).

Established methods exist to develop a PBPK model for any chemical based solely on in vitro and in silico parameters. However, assessment of the predictive accuracies of any PBPK model-derived simulations is highly reliant on the availability of in vivo pharmacokinetic (PK) datasets. This inherently limits the widespread applicability of PBPK modelling to the vast chemical space of non-pharmacological entities whereby there is a paucity of in vivo data. To circumvent this limitation, Ellison et al. introduced a read across framework for evaluating the PBPK model of a target chemical (chemical with no PK data) using PK data from an analogous source chemical (chemical with existing PK data).

In this study, the investigator aims to further evaluate and develop this PK read-across approach to consider non-pharmaceutical compounds. A target compound with no human PK data available was identified, which is a food flavouring agent, terpinolene and its source compound, limonene. A PBPK model for terpinolene will be built and used to compare the in vitro absorption, distribution, metabolism and elimination (ADME) parameters between terpinolene and limonene. To further validate this read-across approach, a prospective clinical study to obtain the missing in vivo PK of terpinolene is proposed.

02

Conditions studied

  • Pharmacokinetics of Terpinolene
03

In context

Lead sponsor

Singapore Institute of Food and Biotechnology Innovation is the lead sponsor of 69 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 21-50
  • Chinese, Malay and Indian ethnicities
  • Male or female
  • Adequate fluency in the English language to understand the process, study instructions and study assessments
  • Sufficient vision and hearing to complete the study procedures
  • Willing and able to participate and to give written informed consent

Exclusion criteria

Exclusion Criteria:

  • Past (\<3 months prior to the study) or current major metabolic, endocrine, gastrointestinal or cardiovascular disease
  • Individuals diagnosed with non-alcoholic fatty liver disease
  • Major surgery in the past 2 months
  • On chronic medication
  • Allergy to olive oil
  • Vegetarian/vegan
  • Smoking
  • Pregnant or lactating
  • Alcohol intake >1 units per day
  • \<18.5 kg/m2 or ≥27 kg/m2
  • Body weight \<54 kg
  • Member of the study team or their immediate family members
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Single arm

    n=15, single oral dose of 200mg of food-grade terpinolene in 5ml of olive oil

    Other: Terpinolene in olive oil

Interventions

  • OtherTerpinolene in olive oil

    Single oral dose of 200mg food-grade terpinolene in 5ml of olive oil

06

What researchers measure

Primary outcomes

  1. Plasma terpinolene concentration

    Blood samples will be collected at 9 timepoints

    Time frame: 24 hours

07

Study locations

1 site
  • Human Development Research Centre, IHDP, A*STAR
    Singapore, 117597, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06691126
Lead sponsor
Singapore Institute of Food and Biotechnology Innovation
Collaborators
Institute for Human Development and Potential (IHDP), Singapore
Responsible party
Chun Yip James Chan (Principal Scientist I, Singapore Institute of Food and Biotechnology Innovation) — Principal investigator
First posted
Nov 15, 2024
Start date
Nov 4, 2024
Primary completion
Dec 3, 2024
Completion
Dec 3, 2024
Last update
Dec 4, 2024

Study contacts

James Chan, PhD
principal investigator · Singapore Institute of Food and Biotechnology Innovation (SIFBI), A*STAR

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion